Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Antibody-dependent enhancement of influenza disease promoted by increase in hemagglutinin stem flexibility and virus fusion kinetics.

Winarski KL, Tang J, Klenow L, Lee J, Coyle EM, Manischewitz J, Turner HL, Takeda K, Ward AB, Golding H, Khurana S.

Proc Natl Acad Sci U S A. 2019 Jul 23;116(30):15194-15199. doi: 10.1073/pnas.1821317116. Epub 2019 Jul 11.

PMID:
31296560
2.

AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization.

Khurana S, Coyle EM, Manischewitz J, King LR, Gao J, Germain RN, Schwartzberg PL, Tsang JS, Golding H; and the CHI Consortium.

NPJ Vaccines. 2018 Oct 1;3:40. doi: 10.1038/s41541-018-0076-2. eCollection 2018.

3.

A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin.

Yu F, Song H, Wu Y, Chang SY, Wang L, Li W, Hong B, Xia S, Wang C, Khurana S, Feng Y, Wang Y, Sun Z, He B, Hou D, Manischewitz J, King LR, Song Y, Min JY, Golding H, Ji X, Lu L, Jiang S, Dimitrov DS, Ying T.

Cell Host Microbe. 2017 Oct 11;22(4):471-483.e5. doi: 10.1016/j.chom.2017.08.011. Epub 2017 Sep 28.

4.

Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy.

Goswami M, Prince G, Biancotto A, Moir S, Kardava L, Santich BH, Cheung F, Kotliarov Y, Chen J, Shi R, Zhou H, Golding H, Manischewitz J, King L, Kunz LM, Noonan K, Borrello IM, Smith BD, Hourigan CS.

J Transl Med. 2017 Jul 10;15(1):155. doi: 10.1186/s12967-017-1252-2.

5.

Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination.

Lin YC, Winokur P, Blake A, Wu T, Manischewitz J, King LR, Romm E, Golding H, Bielekova B.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(1):e196. doi: 10.1212/NXI.0000000000000196. eCollection 2016 Feb.

6.

Oral priming with replicating adenovirus serotype 4 followed by subunit H5N1 vaccine boost promotes antibody affinity maturation and expands H5N1 cross-clade neutralization.

Khurana S, Coyle EM, Manischewitz J, King LR, Ishioka G, Alexander J, Smith J, Gurwith M, Golding H.

PLoS One. 2015 Jan 28;10(1):e0115476. doi: 10.1371/journal.pone.0115476. eCollection 2015.

7.

H5 N-terminal β sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine.

Khurana S, Coyle EM, Verma S, King LR, Manischewitz J, Crevar CJ, Carter DM, Ross TM, Golding H.

Vaccine. 2014 Nov 12;32(48):6421-32. doi: 10.1016/j.vaccine.2014.09.049. Epub 2014 Oct 3.

PMID:
25284811
8.

Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency.

Khurana S, King LR, Manischewitz J, Coyle EM, Golding H.

Vaccine. 2014 Apr 17;32(19):2188-97. doi: 10.1016/j.vaccine.2014.02.049. Epub 2014 Mar 6.

PMID:
24613520
9.

A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response.

Talaat KR, Luke CJ, Khurana S, Manischewitz J, King LR, McMahon BA, Karron RA, Lewis KD, Qin J, Follmann DA, Golding H, Neuzil KM, Subbarao K.

J Infect Dis. 2014 Jun 15;209(12):1860-9. doi: 10.1093/infdis/jiu123. Epub 2014 Mar 5. Erratum in: J Infect Dis. 2014 Dec 15;210(12):2021.

10.

Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease.

Khurana S, Loving CL, Manischewitz J, King LR, Gauger PC, Henningson J, Vincent AL, Golding H.

Sci Transl Med. 2013 Aug 28;5(200):200ra114. doi: 10.1126/scitranslmed.3006366.

11.

DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults.

Khurana S, Wu J, Dimitrova M, King LR, Manischewitz J, Graham BS, Ledgerwood JE, Golding H.

J Infect Dis. 2013 Aug 1;208(3):413-7. doi: 10.1093/infdis/jit178. Epub 2013 Apr 30.

12.

Effects of postchallenge administration of ST-246 on dissemination of IHD-J-Luc vaccinia virus in normal mice and in immune-deficient mice reconstituted with T cells.

Zaitseva M, Shotwell E, Scott J, Cruz S, King LR, Manischewitz J, Diaz CG, Jordan RA, Grosenbach DW, Golding H.

J Virol. 2013 May;87(10):5564-76. doi: 10.1128/JVI.03426-12. Epub 2013 Mar 6.

13.

Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody.

Schmidt AG, Xu H, Khan AR, O'Donnell T, Khurana S, King LR, Manischewitz J, Golding H, Suphaphiphat P, Carfi A, Settembre EC, Dormitzer PR, Kepler TB, Zhang R, Moody MA, Haynes BF, Liao HX, Shaw DE, Harrison SC.

Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):264-9. doi: 10.1073/pnas.1218256109. Epub 2012 Nov 21.

14.

Humans with chronic granulomatous disease maintain humoral immunologic memory despite low frequencies of circulating memory B cells.

Moir S, De Ravin SS, Santich BH, Kim JY, Posada JG, Ho J, Buckner CM, Wang W, Kardava L, Garofalo M, Marciano BE, Manischewitz J, King LR, Khurana S, Chun TW, Golding H, Fauci AS, Malech HL.

Blood. 2012 Dec 6;120(24):4850-8. doi: 10.1182/blood-2012-05-430959. Epub 2012 Oct 16.

15.

H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans.

Khurana S, Wu J, Verma N, Verma S, Raghunandan R, Manischewitz J, King LR, Kpamegan E, Pincus S, Smith G, Glenn G, Golding H.

J Virol. 2011 Nov;85(21):10945-54. doi: 10.1128/JVI.05406-11. Epub 2011 Aug 24.

16.

Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin.

Whittle JR, Zhang R, Khurana S, King LR, Manischewitz J, Golding H, Dormitzer PR, Haynes BF, Walter EB, Moody MA, Kepler TB, Liao HX, Harrison SC.

Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14216-21. doi: 10.1073/pnas.1111497108. Epub 2011 Aug 8.

17.

Passive immunotherapies protect WRvFire and IHD-J-Luc vaccinia virus-infected mice from lethality by reducing viral loads in the upper respiratory tract and internal organs.

Zaitseva M, Kapnick SM, Meseda CA, Shotwell E, King LR, Manischewitz J, Scott J, Kodihalli S, Merchlinsky M, Nielsen H, Lantto J, Weir JP, Golding H.

J Virol. 2011 Sep;85(17):9147-58. doi: 10.1128/JVI.00121-11. Epub 2011 Jun 29.

18.

Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines.

Khurana S, Larkin C, Verma S, Joshi MB, Fontana J, Steven AC, King LR, Manischewitz J, McCormick W, Gupta RK, Golding H.

Vaccine. 2011 Aug 5;29(34):5657-65. doi: 10.1016/j.vaccine.2011.06.014. Epub 2011 Jun 23.

19.

A rapid Flp-In system for expression of secreted H5N1 influenza hemagglutinin vaccine immunogen in mammalian cells.

Lu H, Khurana S, Verma N, Manischewitz J, King L, Beigel JH, Golding H.

PLoS One. 2011 Feb 28;6(2):e17297. doi: 10.1371/journal.pone.0017297.

20.

Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets.

Khurana S, Verma S, Verma N, Crevar CJ, Carter DM, Manischewitz J, King LR, Ross TM, Golding H.

J Virol. 2011 Feb;85(3):1246-56. doi: 10.1128/JVI.02107-10. Epub 2010 Nov 17.

21.

Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus.

Khurana S, Verma S, Verma N, Crevar CJ, Carter DM, Manischewitz J, King LR, Ross TM, Golding H.

PLoS One. 2010 Jul 12;5(7):e11548. doi: 10.1371/journal.pone.0011548.

22.

Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.

Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, Rock MT, Edwards KM, Del Giudice G, Rappuoli R, Golding H.

Sci Transl Med. 2010 Jan 20;2(15):15ra5. doi: 10.1126/scitranslmed.3000624.

23.

A practical influenza neutralization assay to simultaneously quantify hemagglutinin and neuraminidase-inhibiting antibody responses.

Hassantoufighi A, Zhang H, Sandbulte M, Gao J, Manischewitz J, King L, Golding H, Straight TM, Eichelberger MC.

Vaccine. 2010 Jan 8;28(3):790-7. doi: 10.1016/j.vaccine.2009.10.066. Epub 2009 Nov 1.

PMID:
19887135
24.

Application of bioluminescence imaging to the prediction of lethality in vaccinia virus-infected mice.

Zaitseva M, Kapnick SM, Scott J, King LR, Manischewitz J, Sirota L, Kodihalli S, Golding H.

J Virol. 2009 Oct;83(20):10437-47. doi: 10.1128/JVI.01296-09. Epub 2009 Aug 5.

25.

Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model.

Meseda CA, Mayer AE, Kumar A, Garcia AD, Campbell J, Listrani P, Manischewitz J, King LR, Golding H, Merchlinsky M, Weir JP.

Clin Vaccine Immunol. 2009 Sep;16(9):1261-71. doi: 10.1128/CVI.00040-09. Epub 2009 Jul 15.

26.

Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets.

Khurana S, Suguitan AL Jr, Rivera Y, Simmons CP, Lanzavecchia A, Sallusto F, Manischewitz J, King LR, Subbarao K, Golding H.

PLoS Med. 2009 Apr 21;6(4):e1000049. doi: 10.1371/journal.pmed.1000049. Epub 2009 Apr 21.

27.

Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus.

Laddy DJ, Yan J, Khan AS, Andersen H, Cohn A, Greenhouse J, Lewis M, Manischewitz J, King LR, Golding H, Draghia-Akli R, Weiner DB.

J Virol. 2009 May;83(9):4624-30. doi: 10.1128/JVI.02335-08. Epub 2009 Feb 11.

28.

Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.

He Y, Manischewitz J, Meseda CA, Merchlinsky M, Vassell RA, Sirota L, Berkower I, Golding H, Weiss CD.

J Infect Dis. 2007 Oct 1;196(7):1026-32. Epub 2007 Aug 20.

PMID:
17763325
29.

Durable neutralizing antibodies after remote smallpox vaccination among adults with and without HIV infection.

Kan VL, Manischewitz J, King LR, Golding H.

AIDS. 2007 Feb 19;21(4):521-4.

PMID:
17301573
30.

Subunit recombinant vaccine protects against monkeypox.

Heraud JM, Edghill-Smith Y, Ayala V, Kalisz I, Parrino J, Kalyanaraman VS, Manischewitz J, King LR, Hryniewicz A, Trindade CJ, Hassett M, Tsai WP, Venzon D, Nalca A, Vaccari M, Silvera P, Bray M, Graham BS, Golding H, Hooper JW, Franchini G.

J Immunol. 2006 Aug 15;177(4):2552-64.

31.

Clinical and immunological comparison of smallpox vaccine administered to the outer versus the inner upper arms of vaccinia-naive adults.

Waibel KH, Golding H, Manischewitz J, King LR, Tuchscherer M, Topolski RL, Walsh DS.

Clin Infect Dis. 2006 Feb 15;42(4):e16-20. Epub 2006 Jan 10.

PMID:
16421781
32.

Increased CXCR4-dependent HIV-1 fusion in activated T cells: role of CD4/CXCR4 association.

Zaitseva M, Romantseva T, Manischewitz J, Wang J, Goucher D, Golding H.

J Leukoc Biol. 2005 Dec;78(6):1306-17. Epub 2005 Oct 4.

PMID:
16204649
33.

Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.

Meseda CA, Garcia AD, Kumar A, Mayer AE, Manischewitz J, King LR, Golding H, Merchlinsky M, Weir JP.

Virology. 2005 Sep 1;339(2):164-75.

34.

Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus.

Edghill-Smith Y, Golding H, Manischewitz J, King LR, Scott D, Bray M, Nalca A, Hooper JW, Whitehouse CA, Schmitz JE, Reimann KA, Franchini G.

Nat Med. 2005 Jul;11(7):740-7. Epub 2005 Jun 12.

PMID:
15951823
35.

Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge.

Edghill-Smith Y, Bray M, Whitehouse CA, Miller D, Mucker E, Manischewitz J, King LR, Robert-Guroff M, Hryniewicz A, Venzon D, Meseda C, Weir J, Nalca A, Livingston V, Wells J, Lewis MG, Huggins J, Zwiers SH, Golding H, Franchini G.

J Infect Dis. 2005 Feb 1;191(3):372-81. Epub 2005 Jan 4.

PMID:
15633096
36.

Intravenous immunoglobulin products contain neutralizing antibodies to vaccinia.

Goldsmith JC, Eller N, Mikolajczyk M, Manischewitz J, Golding H, Scott DE.

Vox Sang. 2004 Feb;86(2):125-9.

PMID:
15023182
37.

Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques.

Edghill-Smith Y, Venzon D, Karpova T, McNally J, Nacsa J, Tsai WP, Tryniszewska E, Moniuszko M, Manischewitz J, King LR, Snodgrass SJ, Parrish J, Markham P, Sowers M, Martin D, Lewis MG, Berzofsky JA, Belyakov IM, Moss B, Tartaglia J, Bray M, Hirsch V, Golding H, Franchini G.

J Infect Dis. 2003 Oct 15;188(8):1181-91. Epub 2003 Oct 10.

PMID:
14551889
38.

Development of a novel vaccinia-neutralization assay based on reporter-gene expression.

Manischewitz J, King LR, Bleckwenn NA, Shiloach J, Taffs R, Merchlinsky M, Eller N, Mikolajczyk MG, Clanton DJ, Monath T, Weltzin RA, Scott DE, Golding H.

J Infect Dis. 2003 Aug 1;188(3):440-8. Epub 2003 Jul 16.

PMID:
12870127
39.

Inhibition of HIV-1 infection by a CCR5-binding cyclophilin from Toxoplasma gondii.

Golding H, Aliberti J, King LR, Manischewitz J, Andersen J, Valenzuela J, Landau NR, Sher A.

Blood. 2003 Nov 1;102(9):3280-6. Epub 2003 Jul 10.

40.

CXCR4 heterogeneity in primary cells: possible role of ubiquitination.

Lapham CK, Romantseva T, Petricoin E, King LR, Manischewitz J, Zaitseva MB, Golding H.

J Leukoc Biol. 2002 Dec;72(6):1206-14.

PMID:
12488503
41.

Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates.

Golding H, Zaitseva M, de Rosny E, King LR, Manischewitz J, Sidorov I, Gorny MK, Zolla-Pazner S, Dimitrov DS, Weiss CD.

J Virol. 2002 Jul;76(13):6780-90.

42.
43.

Interferon gamma and interleukin 6 modulate the susceptibility of macrophages to human immunodeficiency virus type 1 infection.

Zaitseva M, Lee S, Lapham C, Taffs R, King L, Romantseva T, Manischewitz J, Golding H.

Blood. 2000 Nov 1;96(9):3109-17.

44.

Coreceptor competition for association with CD4 may change the susceptibility of human cells to infection with T-tropic and macrophagetropic isolates of human immunodeficiency virus type 1.

Lee S, Lapham CK, Chen H, King L, Manischewitz J, Romantseva T, Mostowski H, Stantchev TS, Broder CC, Golding H.

J Virol. 2000 Jun;74(11):5016-23.

45.

A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates.

Landry ML, Stanat S, Biron K, Brambilla D, Britt W, Jokela J, Chou S, Drew WL, Erice A, Gilliam B, Lurain N, Manischewitz J, Miner R, Nokta M, Reichelderfer P, Spector S, Weinberg A, Yen-Lieberman B, Crumpacker C.

Antimicrob Agents Chemother. 2000 Mar;44(3):688-92.

46.

Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis.

Whitcup SM, Fortin E, Lindblad AS, Griffiths P, Metcalf JA, Robinson MR, Manischewitz J, Baird B, Perry C, Kidd IM, Vrabec T, Davey RT Jr, Falloon J, Walker RE, Kovacs JA, Lane HC, Nussenblatt RB, Smith J, Masur H, Polis MA.

JAMA. 1999 Nov 3;282(17):1633-7.

PMID:
10553789
47.

Flow cytometric determination of ganciclovir susceptibilities of human cytomegalovirus clinical isolates.

McSharry JM, Lurain NS, Drusano GL, Landay A, Manischewitz J, Nokta M, O'Gorman M, Shapiro HM, Weinberg A, Reichelderfer P, Crumpacker C.

J Clin Microbiol. 1998 Apr;36(4):958-64.

48.

Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection.

Zaitseva M, Blauvelt A, Lee S, Lapham CK, Klaus-Kovtun V, Mostowski H, Manischewitz J, Golding H.

Nat Med. 1997 Dec;3(12):1369-75.

PMID:
9396607
49.

Enhancement of human immunodeficiency virus type 1 envelope-mediated fusion by a CD4-gp120 complex-specific monoclonal antibody.

Lee S, Peden K, Dimitrov DS, Broder CC, Manischewitz J, Denisova G, Gershoni JM, Golding H.

J Virol. 1997 Aug;71(8):6037-43.

50.

Lack of clinical utility of bronchoalveolar lavage cultures for cytomegalovirus in HIV infection.

Mann M, Shelhamer JH, Masur H, Gill VJ, Travis W, Solomon D, Manischewitz J, Stock F, Lane HC, Ognibene FP.

Am J Respir Crit Care Med. 1997 May;155(5):1723-8.

PMID:
9154883

Supplemental Content

Loading ...
Support Center